Citations

Clear

3030 citation(s) found for "Susan, M".

Improving Instructions to Stop the Bleed
Forsyth, Katherine L., Lowndes, Bethany R. , Jonson, Carl‐Oscar , Sztajnkrycer, Matthew D. , Heller, Stephanie F. , Blocker, Renaldo C., Forsyth, Katherine L., Prytz, Erik , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | September 28, 2017 | Volume: 61 | Issue: 1 | Pages: 588-592

10.1177/1541931213601631 Get It

The Stop The Bleed initiative was developed by the Department of Homeland Security to educate lay providers in bleeding reduction strategies. The current study evaluated: (1)three tourniquet instructions using a simulated tourniquet task and (2)participant confidence levels in tourniquet use and lay provider training. Thirty participants with limited clinical experience applied a tourniquet to a simulated limb using one of three instruction sets. Twelve of these participants (40%) participated in a tourniquet training session and focus group to discuss each instruction set. Participants preferred the most simple and pictoral instruction set, and identified opportunities for improvement in each set. Participant confidence in tourniquet use increased significantly following the task and the focus group. After the focus group, participant confidence in instructing lay providers on proper tourniquet use significantly increased. Adding key steps, contextual pictures, and indicators of success to instructions could support lay providers stop the bleed in life-threatening situations.
Dexmedetomidine as Part of a Multimodal Analgesic Treatment Regimen for Opioid Induced Hyperalgesia in a Patient with Significant Opioid Tolerance
Patch, Richard K. , Eldrige, Jason S. , Moeschler, Susan M. , Pingree, Matthew J. , Patch Iii, Richard K

Mayo Clinic

Case Reports in Anesthesiology | September 25, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-5

10.1155/2017/9876306 | PMID 29147587 Get It

Acute postoperative pain in patients with opioid tolerance creates a significant management challenge for anesthesiologists and pain medicine physicians. A multimodal approach is key; however other factors can complicate management such as opioid induced hyperalgesia. We present the case of a patient on large amounts of intrathecal opioids for chronic pain syndrome with opioid induced hyperalgesia after an exploratory laparotomy. Dexmedetomidine was utilized successfully as part of a controlled multimodal analgesic plan and should be a consideration for opioid tolerant patients experiencing opioid induced hyperalgesia.
Utilization of Leads After Permanent Implant in Spinal Cord Stimulator Systems
Sanders, Rebecca A., Hoelzer, Bryan C. , Bendel, Markus A. , Lamer, Tim J. , Eldrige, Jason S. , Pingree, Matthew J. , Moeschler, Susan M. , Gazelka, Halena M. , Mauck, William D. , Rho, Richard H., Mauck, W David, Pittelkow, Thomas P.

Mayo Clinic

Pain Practice | September 23, 2017 | Volume: 18 | Issue: 5 | Pages: 562-567

10.1111/papr.12644 | PMID 28941145 Get It

AbstractObjectiveThe goal of this study was to determine the frequency and clinical indications associated with implantation of single vs. dual percutaneous lead spinal cord stimulator (SCS) systems and to look further into how these leads are utilized for treatment.Materials and MethodsA retrospective cohort analysis of all patients undergoing SCS implantation between January 2001 and December 2013 with a minimum of 2 years of clinical follow‐up was performed. Number of trial leads and implanted leads was recorded. For patients with dual‐lead systems, it was noted if and when the second lead was used, along with the clinical indication for lead activation.ResultsIn the 259‐patient cohort, 15.8% (n = 41) patients underwent placement of a single‐lead system, 83.0% (n = 215) underwent placement of a dual‐lead system, and 1.2% (n = 3) underwent placement of 3‐lead systems. Placement of dual‐lead systems was similar among all indication groups. Of those patients with a dual‐lead system in place, 88.1% utilized both leads and average time to programming of the second lead was 2.3 months. The most common reason to activate the second lead was inadequate stimulation coverage. Five of the 41 patients with single‐lead systems underwent an additional surgery to implant a second lead due to inadequate stimulation with 1 lead.ConclusionsTo our knowledge this is the first descriptive analysis of the frequency of single‐ and dual‐lead SCS systems. This report indicates that dual‐lead systems are most often placed and both leads are required for optimal patient therapy.
Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings
Hampel, Paul J. , Chaffee, Kari G. , King, Rebecca L. , Simonetto, Douglas A. , Achenbach, Sara J., Call, Timothy G. , Ding, Wei , Leis, José F., Chanan‐Khan, Asher , Bowen, Deborah A., Conte, Michael, Schwager, Susan M., Hanson, Curtis A. , Parikh, Sameer A. , Rabe, Kari G. , SIMONETTO, DOUGLAS, Achenbach, Sara, Ding, Wei , Kenderian, Saad S. , Chanan-Khan, Asher A., Conte, Michael J, Parikh, Sameer A , Hampel, Paul J , Larson, Melissa C. , Slager, Susan L. , Kay, Neil E. , Shanafelt, Tait D. , Simonetto, Douglas A

Mayo Clinic

American Journal of Hematology | September 22, 2017 | Volume: 92 | Issue: 12 | Pages: 1362-1369

10.1002/ajh.24915 | PMID 28940587 Get It

AbstractThe prevalence of liver dysfunction and its association with outcomes in patients with previously untreated chronic lymphocytic leukemia (CLL) is unknown. Newly diagnosed (<12 months) previously untreated CLL patients seen at Mayo Clinic, Rochester, MN between 9/1993 and 4/2016 who had baseline assessment of at least one liver function test (LFT) were included in this analysis. The prevalence of liver dysfunction at baseline, proportion of patients who acquired LFT abnormalities, time to first therapy (TTFT) and overall survival (OS) were assessed. An abnormal LFT was present in 82/2336 (3.5%) patients at diagnosis and was associated with advanced Rai stage (Rai III–IV) (21% vs. 6%; P < .001), lower hemoglobin (13.1 g/dL vs. 13.9 g/dL; P < .001), and lower platelet count (187 × 109/L vs. 200 × 109/L; P = .03). Additionally, 236 patients with normal LFTs at diagnosis developed acquired liver dysfunction during follow‐up. Patients with abnormal LFTs at diagnosis had a shorter OS compared to those with normal LFTs (HR 1.80 95% CI 1.13‐2.87; P = .014, adjusted for age, sex, Rai stage, and treatment), although TTFT was not different. Of 52 patients who underwent a liver biopsy, CLL was present in liver tissue in 39/52 (73%) patients, with the portal tracts the most common region involved. Histopathology findings of liver involvement by CLL had limited correlation with choice of CLL therapy. In conclusion, approximately 1 of 25 newly diagnosed CLL patients has abnormal LFTs at diagnosis. Although the TTFT was not different among patients with abnormal LFTs, these patients have a shorter OS compared to those with normal LFTs.
OC01.03: Incidence of stillbirth is increased in familial LQTS: a retrospective study from eight international centres
Swan, Heikki, Clur, Sally-Ann B., Etheridge, Susan P. , Isberg, Helena Kornfält , Benson, D. Woodrow , Cuneo, Bettina F. , Clur, Sally‐Ann B. , Winbo, Annika , Haugaa, Kristina H. , Schwartz, Peter J. , Ackerman, Michael

Mayo Clinic

Ultrasound in Obstetrics & Gynecology | September 18, 2017 | Volume: 50 | Issue: S1 | Pages: 2-2

10.1002/uog.17572 Get It

History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
Minlikeeva, Albina N. , Freudenheim, Jo L. , Eng, Kevin H., Cannioto, Rikki , Friel, Grace , Szender, J. Brian, Odunsi, Kunle , Mayor, Paul , Diergaarde, Brenda , Zsíros, Emese , Kelemen, Linda E. , Köbel, Martin , Steed, Helen , DeFazio, Anna , Jordan, Susan J. , Fasching, Peter A. , Beckmann, Matthias W. , Rossing, Mary Anne, Chang‐Claude, Jenny , Goodman, Marc T. , Dörk, Thilo , Edwards, Robert P., Ness, Roberta B., Matsuo, Keitaro , Goode, Ellen L. , Høgdall, Estrid , Schildkraut, Joellen M. , Terry, Kathryn L. , Paddock, Lisa E. , Kiemeney, Lambertus A. , Massuger, Leon F.A.G. , Sutphen, Rebecca , Menon, Usha , Gayther, Simon A. , Ramus, Susan J. , Pearce, Celeste Leigh , Wu, Anna H. , Kupryjańczyk, Jolanta , Jensen, Allan , Webb, Penelope M. , Moysich, Kirsten B. , Bowtell, David D.L. , Fazio, Anna de , Dörk, Thilo , Kiemeney, Lambertus A , Ramus, Susan J , Webb, Penelope M , Köbel, Martin , Jensen, Allan , Menon, Usha , Moysich, Kirsten , Matsuo, Keitaro , Kupryjanczyk, Jolanta , Høgdall, Estrid , Bowtell, David D , Segal, Brahm H. , Risch, Harvey A. , Doherty, Jennifer A. , Modugno, Francesmary , Mizuno, Mika , Karlan, Beth Y. , Kjær, Susanne K. , Cramer, Daniel W. , Bandera, Elisa V. , Anton‐Culver, Hoda , Ziogas, Argyrios , Gentry‐Maharaj, Aleksandra , Diergaarde, Brenda , Steed, Helen , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 1, 2017 | Volume: 26 | Issue: 9 | Pages: 1470-1473

10.1158/1055-9965.epi-17-0367 | PMID 28864456 Get It

Abstract Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients. Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes. Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced). Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival. Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. Cancer Epidemiol Biomarkers Prev; 26(9); 1470–3. ©2017 AACR.
Letter: Surgical Decision Making From Image-Based Biophysical Modeling of Glioblastoma: Not Ready for Primetime
Johnston, Sandra K. , Canoll, Peter , Bruce, Jeffrey N. , Swanson, Kristin R. , Massey, Susan Christine , Swanson, Kristin R , Bendok, Bernard R.

Mayo Clinic

Neurosurgery | August 29, 2017 | Volume: 82 | Issue: 1 | Pages: E17-E18

10.1093/neuros/nyx481 | PMID 29029349 Get It

A case‐control evaluation of fungiform papillae density in burning mouth syndrome
Naud, Jason M., Benca, Laura, Drangsholt, Mark, LeResche, Linda, Coldwell, Susan E.

Mayo Clinic

The Laryngoscope | August 22, 2017 | Volume: 128 | Issue: 4 | Pages: 841-846

10.1002/lary.26828 | PMID 28833164 Get It

Hypothesis It has been hypothesized that high fungiform papillae density may be a risk factor for developing the taste and pain alterations characteristic of burning mouth syndrome. Objective Evaluate whether fungiform papillae density, taste sensitivity, and mechanical pain sensitivity differ between burning mouth syndrome cases and controls. Study Design This case‐control study compared cases diagnosed with primary burning mouth syndrome with pain‐free controls. Methods Participants (17 female cases and 23 female controls) rated the intensity of sucrose, sodium chloride, citric acid, and quinine applied separately to each side of the anterior tongue and sampled whole mouth. Mechanical pain sensitivity was assessed separately for each side of the tongue using weighted pins. Digital photographs of participants' tongues were used to count fungiform papillae. Results Burning mouth syndrome cases had increased whole mouth taste intensity. Cases also had increased sensitivity to quinine on the anterior tongue, as well as increased mechanical pain sensitivity on the anterior tongue. Fungiform papillae density did not differ significantly between cases and controls. Fungiform papillae density on the left and right sides of the tongue were correlated in controls; however, there was no left/right side correlation in cases. Conclusion Cases had increased pain and taste perception on the anterior tongue. The lack of correlation between left and right fungiform papillae density in cases may be an indication of asymmetrical lingual innervation in these patients. Level of Evidence 3b. Laryngoscope , 128:841–846, 2018
Whole genome sequencing identifies etiology of recurrent male intrauterine fetal death
Shehab, Omar , Tester, David J. , Ackerman, Nicholas C., Cowchock, F. Susan, Ackerman, Michael J.

Mayo Clinic

Prenatal Diagnosis | August 18, 2017 | Volume: 37 | Issue: 10 | Pages: 1040-1045

10.1002/pd.5142 | PMID 28833278 Get It

AbstractObjectiveTo identify the underlying genetic cause for recurrent intrauterine fetal death (IUFD) of males.MethodsWhole genome sequencing was performed on DNA from five healthy obligatory carrier females and an unaffected male offspring of a multigenerational pedigree with recurrent second‐trimester IUFD of males (n = 19). When documented, all deaths occurred at ≤20 weeks of gestation. Hydrops fetalis was diagnosed at death in the most recent case.ResultsFollowing variant filtering based on a recessive X‐linked inheritance pattern, a rare FOXP3 frameshift mutation (p.D303fs*87) that results in a premature truncation of the protein was discovered. Sanger sequencing confirmed the mutation in the affected fetus. The FOXP3 gene encodes for a transcriptional regulator critical to the function of regulatory T cells. FOXP3 mutations are associated with immune dysregulation, polyendocrinopathy, enteropathy, and X‐linked (IPEX) syndrome which exclusively affects males and may present with a potentially life‐threatening complex autoimmune disorder in early childhood.ConclusionsHere, we demonstrate the utility of whole genome sequencing‐based pedigree analysis to identify the genetic cause for recurrent IUFD when chromosome studies, including microarray analysis, are normal. Further studies are needed to determine the prevalence of FOXP3‐mediated IUFD in males. © 2017 John Wiley & Sons, Ltd.
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
Souza, Jonas A. de, Geyer, Susan M. , Wirth, Lori J. , Menefee, Michael E., Liu, Stephen V. , Shah, Komal , Wright, John, Shah, Manisha H. , Cabanillas, Maria E. , de Souza, Jonas A, Wright, John, Liu, Stephen V

Mayo Clinic

Journal of Clinical Oncology | August 17, 2017 | Volume: 35 | Issue: 29 | Pages: 3315-3321

10.1200/jco.2017.73.0226 | PMID 28817373 Get It

Purpose Sorafenib and lenvatinib are oral multikinase inhibitors targeting vascular endothelial growth factor receptor (VEGFR) and approved for radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). However, there are no approved second- or third-line therapies. MET is implicated in resistance to VEGFR inhibitors. Cabozantinib is an oral multikinase inhibitor targeting MET in addition to VEGFR and is approved for medullary thyroid cancer. In a phase I study of cabozantinib, five of eight patients with DTC previously treated with a VEGFR-targeted therapy had an objective response to cabozantinib. Patients and Methods Patients with RAI-refractory disease with Response Evaluation Criteria in Solid Tumor (RECIST) measurable disease and evidence of progression on prior VEGFR-targeted therapy were enrolled in this single-arm phase II study. The cabozantinib starting dose was 60 mg/day orally but could be escalated to 80 mg if the patient did not experience a response. Patients underwent tumor assessment according to RECIST v1.1 every 8 weeks. In this study, if at least five of 25 response-evaluable patients had an objective response, cabozantinib would be considered a promising agent in this patient population. Results Twenty-five patients were enrolled. The median age was 64 years, and 64% of patients were men. Twenty-one patients had received only one prior VEGFR-targeted therapy (sorafenib, pazopanib, or cediranib), and four patients had received two such therapies. The most common treatment-related adverse events were fatigue, weight loss, diarrhea, palmar-plantar erythrodysesthesia, and hypertension. One drug-related death was noted. Of the 25 patients, 10 (40%) had a partial response, 13 (52%) had stable disease, and two (8%) had nonevaluable disease. The median progression-free survival and overall survival were 12.7 months and 34.7 months, respectively. Conclusion Cabozantinib demonstrated clinically significant, durable objective response activity in patients with RAI-refractory DTC who experienced disease progression while taking prior VEGFR-targeted therapy.